<?xml version="1.0" encoding="UTF-8"?>
<akn:akomaNtoso xmlns:akn="http://docs.oasis-open.org/legaldocml/ns/akn/3.0"><akn:act><akn:meta><akn:identification source="#cosilico"><akn:FRBRWork prescriptive="true" authoritative="true"><akn:FRBRuri value="/akn/us/usc/42/1395m–1" /><akn:FRBRdate date="2025-12-31" name="retrieval" /><akn:FRBRauthor href="#us-congress" /><akn:FRBRcountry value="us" /></akn:FRBRWork><akn:FRBRExpression><akn:FRBRuri value="/akn/us/usc/42/1395m–1/eng@2025" /><akn:FRBRdate date="2025-12-31" /><akn:FRBRauthor href="#cosilico" /><akn:FRBRlanguage language="en" /></akn:FRBRExpression><akn:FRBRManifestation><akn:FRBRuri value="/akn/us/usc/42/1395m–1/eng@2025/main.xml" /><akn:FRBRdate date="2025-12-31" /><akn:FRBRauthor href="#cosilico" /></akn:FRBRManifestation></akn:identification></akn:meta><akn:body><akn:section eId="sec_1395m_1"><akn:num>1395m–1</akn:num><akn:heading>Improving policies for clinical diagnostic laboratory tests</akn:heading><akn:content><akn:p>§ 1395m–1. Improving policies for clinical diagnostic laboratory tests(a) Reporting of private sector payment rates for establishment of medicare payment rates(1) In general(A) General reporting requirementsSubject to subparagraph (B), beginning January 1, 2016, and every 3 years thereafter (or, annually, in the case of reporting with respect to an advanced diagnostic laboratory test, as defined in subsection (d)(5)), an applicable laboratory (as defined in paragraph (2)) shall report to the Secretary, at a time specified by the Secretary (referred to in this subsection as the “reporting period”), applicable information (as defined in paragraph (3)) for a data collection period (as defined in paragraph (4)) for each clinical diagnostic laboratory test that the laboratory furnishes during such period for which payment is made under this part.


(B) Revised reporting periodIn the case of reporting with respect to clinical diagnostic laboratory tests that are not advanced diagnostic laboratory tests, the Secretary shall revise the reporting period under subparagraph (A) such that—(i) no reporting is required during the period beginning January 1, 2020, and ending January 31, 2026;

(ii) reporting is required during the period beginning February 1, 2026, and ending April 30, 2026; and

(iii) reporting is required every three years after the period described in clause (ii).



(2) Definition of applicable laboratoryIn this section, the term “applicable laboratory” means a laboratory that, with respect to its revenues under this subchapter, a majority of such revenues are from this section, section 1395l(h) of this title, or section 1395w–4 of this title. The Secretary may establish a low volume or low expenditure threshold for excluding a laboratory from the definition of applicable laboratory under this paragraph, as the Secretary determines appropriate.


(3) Applicable information defined(A) In generalIn this section, subject to subparagraph (B), the term “applicable </akn:p></akn:content><akn:subsection eId="subsec_1395m_1_a"><akn:num>(a)</akn:num><akn:heading>Reporting of private sector payment rates for establishment of medicare payment rates</akn:heading><akn:content><akn:p>(a) Reporting of private sector payment rates for establishment of medicare payment rates</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_1395m_1_b"><akn:num>(b)</akn:num><akn:heading>Payment for clinical diagnostic laboratory tests</akn:heading><akn:content><akn:p>(b) Payment for clinical diagnostic laboratory tests</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_1395m_1_c"><akn:num>(c)</akn:num><akn:heading>Payment for new tests that are not advanced diagnostic laboratory tests</akn:heading><akn:content><akn:p>(c) Payment for new tests that are not advanced diagnostic laboratory tests</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_1395m_1_d"><akn:num>(d)</akn:num><akn:heading>Payment for new advanced diagnostic laboratory tests</akn:heading><akn:content><akn:p>(d) Payment for new advanced diagnostic laboratory tests</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_1395m_1_e"><akn:num>(e)</akn:num><akn:heading>Coding</akn:heading><akn:content><akn:p>(e) Coding</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_1395m_1_f"><akn:num>(f)</akn:num><akn:heading>Input from clinicians and technical experts</akn:heading><akn:content><akn:p>(f) Input from clinicians and technical experts</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_1395m_1_g"><akn:num>(g)</akn:num><akn:heading>Coverage</akn:heading><akn:content><akn:p>(g) Coverage</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_1395m_1_h"><akn:num>(h)</akn:num><akn:heading>Implementation</akn:heading><akn:content><akn:p>(h) Implementation</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_1395m_1_i"><akn:num>(i)</akn:num><akn:heading>Transitional rule</akn:heading><akn:content><akn:p>(i) Transitional rule During the period beginning on April 1, 2014, and ending on December 31, 2016, with respect to advanced diagnostic laboratory tests under this part, the Secretary shall use the methodologies for pricing, coding, and coverage in effect on the day before April 1, 2014, which may include cross-walking or gapfilling methods.</akn:p></akn:content></akn:subsection></akn:section></akn:body></akn:act></akn:akomaNtoso>